Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Gynecologic 7Breast 6Thoracic 5Genitourinary 5Sarcoma 3Head & Neck 3Plasma cell 2Other hematologic neoplasm 2Dermatologic 2CNS 2Other solid neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 13Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Follicular 8Myelodysplastic Syndromes 7Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Biphenotypic, Acute 5Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Mycosis Fungoides 3Melanoma 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Chronic 3Immunoblastic Lymphadenopathy 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2

Interventions

Specimen Handling 2Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Counseling 2Bupropion 2vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1tanespimycin 1sapanisertib 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine phosphate 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1capmatinib 1capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × Magnetic Resonance Spectroscopy × Other hematologic neoplasm × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡